In last trading session, Arcus Biosciences Inc (NYSE:RCUS) saw 2.5 million shares changing hands with its beta currently measuring 0.88. Company’s recent per share price level of $16.46 trading at $0.73 or 4.64% at ring of the bell on the day assigns it a market valuation of $1.50B. That closing price of RCUS’s stock is at a discount of -23.39% from its 52-week high price of $20.31 and is indicating a premium of 21.32% from its 52-week low price of $12.95. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.83 million shares which gives us an average trading volume of 675.55K if we extend that period to 3-months.
For Arcus Biosciences Inc (RCUS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.54. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.17 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcus Biosciences Inc (NYSE:RCUS) trade information
Upright in the green during last session for gaining 4.64%, in the last five days RCUS remained trading in the green while hitting it’s week-highest on Thursday, 11/07/24 when the stock touched $16.46 price level, adding 1.73% to its value on the day. Arcus Biosciences Inc’s shares saw a change of -13.82% in year-to-date performance and have moved 7.58% in past 5-day. Arcus Biosciences Inc (NYSE:RCUS) showed a performance of -7.22% in past 30-days. Number of shares sold short was 6.34 million shares which calculate 9.97 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 32 to the stock, which implies a rise of 48.56% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 46. It follows that stock’s current price would drop -21.51% in reaching the projected high whereas dropping to the targeted low would mean a loss of -21.51% for stock’s current value.
Arcus Biosciences Inc (RCUS) estimates and forecasts
Statistics highlight that Arcus Biosciences Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 1.92% of value to its shares in past 6 months, showing an annual growth rate of 21.69% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 116.30% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 29.95M for the same. And 5 analysts are in estimates of company making revenue of 40.7M in the next quarter. Company posted 31M and 33.86M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -23.70% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 20.39% while estimates for its earnings growth in next 5 years are of 7.80%.
Arcus Biosciences Inc (NYSE:RCUS)’s Major holders
Insiders are in possession of 40.64% of company’s total shares while institution are holding 58.24 percent of that, with stock having share float percentage of 98.10%. Investors also watch the number of corporate investors in a company very closely, which is 58.24% institutions for Arcus Biosciences Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at RCUS for having 9.76 million shares of worth $148.69 million. And as of 2024-06-30, it was holding 11.3261 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 5.26 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.099 of outstanding shares, having a total worth of $80.07 million.
